Comparison analysis of gene expression patterns between sporadic Alzheimer's and Parkinson's disease

Journal of Alzheimer's Disease

Volumn 12, Issue 4, 2007, Pages 291-311

  Grünblatt, Edna ^a   Zander, Nicole ^a   Bartl, Jasmin ^a   Jie, Li ^a   Monoranu, Camelia Maria ^a   Arzberger, Thomas ^a   Ravid, Rivka ^b   Roggendorf, Wolfgang ^a   Gerlach, Manfred ^a   Riederer, Peter ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b NETHERLANDS BRAIN BANK   (Netherlands)

Author keywords

Affymetrix; Alzheimer's disease; Gene chip; Gene expression; Microarray; Parkinson's disease; Quantitative RT PCR

Indexed keywords

COMPLEMENTARY RNA; DNA; RNA; RNA 18S;

AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BRAIN TISSUE; CEREBELLUM; COMPARATIVE STUDY; CONTROLLED STUDY; DEGENERATIVE DISEASE; EARLY DIAGNOSIS; FEMALE; FRONTAL LOBE; GENE EXPRESSION; HIPPOCAMPUS; HUMAN; HUMAN GENOME; HUMAN TISSUE; MALE; NEUROLOGIC DISEASE; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 38049064079     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2007-12402     Document Type: Article

References (87)

1. A. Alzheimer, R.A. Stelzmann, H.N. Schnitzlein and F.R. Murtagh, An English translation of Alzheimer's 1907 paper, Uber eine eigenartige Erkankung der Hirnrinde, Clin Anat 8 (1995) , 429-431.
2. C. Bancher, H. Braak, P. Fischer and K.A. Jellinger, Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer's and Parkinson's disease patients, Neurosci Lett 162 (1993), 179-182.
3. C. Barlow and D.J. Lockhart, DNA arrays and neurobiology-what's new and what's next? Curr Opin Neurobiol 12 (2002), 554-561.
4. M.F. Beal, Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment, J Bioenerg Biomembr 36 (2004), 381-386.
5. C. Benito, E. Nunez, R.M. Tolon, E.J. Carrier, A. Rabano, C.J. Hillard and J. Romero, Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains, J Neurosci 23 (2003), 11136-11141.
6. S.L. Berger, Histone modifications in transcriptional regulation, Curr Opin Genet Dev 12 (2002), 142-148.
7. M.E. Blomqvist, P.A. Silburn, D.D. Buchanan, N. Andreasen, K. Blennow, N.L. Pedersen, A.J. Brookes, G.D. Mellick and J.A. Prince, Sequence variation in the proximity of IDE may impact age at onset of both Parkinson disease and Alzheimer disease, Neurogenetics 5 (2004), 115-119.
8. F. Boller, T. Mizutani, U. Roessmann and P. Gambetti, Parkinson disease, dementia, and Alzheimer disease: clinicopathological correlations, Ann Neurol 7 (1980), 329-335.
9. S.J. Bolton, M. Russelakis-Carneiro, S. Betmouni and V.H. Perry, Non-nuclear histone H1 is upregulated in neurones and astrocytes in prion and Alzheimer's diseases but not in acute neurodegeneration, Neuropathol Appl Neurobiol 25 (1999), 425-432.
10. H. Braak and E. Braak, Neuropathological stageing of Alzheimer-related changes, Acta Neuropathol (Berl) 82 (1991), 239-259.
11. H. Braak, E. Braak, D. Yilmazer, R.A. de Vos, E.N. Jansen and J. Bohl, Pattern of brain destruction in Parkinson's and Alzheimer's diseases, J Neural Transm 103 (1996), 455-490.
12. H. Braak, E. Ghebremedhin, U. Rub, H. Bratzke and K. Del Tredici, Stages in the development of Parkinson's disease-related pathology, Cell Tissue Res 318 (2004), 121-134.
13. C.F. Burant, M.K. Treutelaar and M.G. Buse, Diabetes-induced functional and structural changes in insulin receptors from rat skeletal muscle, J Clin Invest 77 (1986), 260-270.
14. C.Y. Chung, H. Seo, K.C. Sonntag, A. Brooks, L. Lin and O. Isacson, Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection, Hum Mol Genet 14 (2005), 1709-1725.
15. G.A. Churchill and B. Oliver, Sex, flies and microarrays, Nat Genet 29 (2001), 355-356.
16. C. Clarck, D. Ewbank, V.-Y. Lee and T. JQ, Molecular pathology of Alzheimer's disease: neuronal cytoskeletal abnormalities, in: The dementias, (Vol. 19), J. Growdon and R. MN, eds, 1998, pp. 285-304, Butterworth Heinemann, Boston.
17. V. Colangelo, J. Schurr, M.J. Ball, R.P. Pelaez, N.G. Bazan and W.J. Lukiw, Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: transcription and neurotrophic factor down-regulation and up-regulation of apoptotic and proinflammatory signaling, J Neurosci Res 70 (2002), 462-473.
18. J.R. Currie, N.C. Chen-Hwang, R. Denman, M. Smedman, A. Potempska, N. Ramakrishna, R. Rubenstein, H.M.Wisniewski and D.L. Miller, Reduction of histone cytotoxicity by the Alzheimer beta-amyloid peptide precursor, Biochim Biophys Acta 1355 (1997), 248-258.
19. C. Debouck and P.N. Goodfellow, DNA microarrays in drug discovery and development, Nat Genet 21 (1999), 48-50.
20. J. DeRisi, L. Penland, P.O. Brown, M.L. Bittner, P.S. Meltzer, M. Ray, Y. Chen, Y.A. Su and J.M. Trent, Use of a cDNA microarray to analyse gene expression patterns in human cancer, Nat Genet 14 (1996), 457-460.
21. J. DeRisi, B. van den Hazel, P. Marc, E. Balzi, P. Brown, C. Jacq and A. Goffeau, Genome microarray analysis of transcriptional activation in multidrug resistance yeast mutants, FEBS Lett 470 (2000), 156-160.
22. J.A. Duce, D.P. Smith, R.E. Blake, P.J. Crouch, Q.X. Li, C.L. Masters and I.A. Trounce, Linker histone H1 binds to disease associated amyloid-like fibrils, J Mol Biol 361 (2006), 493-505.
23. J. Fernandez-Ruiz, I. Lastres-Becker, A. Cabranes, S. Gonzalez and J.A. Ramos, Endocannabinoids and basal ganglia functionality, Prostaglandins Leukot Essent Fatty Acids 66 (2002), 257-267.
24. A. Fuso, L. Seminara, R.A. Cavallaro, F. D'Anselmi and S. Scarpa, S-adenosylmethionine/homocysteine cycle alterations modify DNA methylation status with consequent deregulation of PS1 and BACE and beta-amyloid production, Mol Cell Neurosci 28 (2005), 195-204.
25. P. Gaspar and F. Gray, Dementia in idiopathic Parkinson's disease. A neuropathological study of 32 cases, Acta Neuropathol (Berl) 64 (1984), 43-52.
26. B.I. Giasson, H. Ischiropoulos, V.M. Lee and J.Q. Trojanowski, The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer's and Parkinson's diseases, Free Radic Biol Med 32 (2002), 1264-1275.
27. C. Gotti, M. Moretti, I. Bohr, I. Ziabreva, S. Vailati, R. Longhi, L. Riganti, A. Gaimarri, I.G. McKeith, R.H. Perry, D. Aarsland, J.P. Larsen, E. Sher, R. Beattie, F. Clementi and J.A. Court, Selective nicotinic acetylcholine receptor subunit deficits identified in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies by immunoprecipitation, Neurobiol Dis 23 (2006), 481-489.
28. H. Grossman, C. Bergmann and S. Parker, Dementia: a brief review, Mt Sinai J Med 73 (2006), 985-992.
29. E. Gr̈unblatt, The benefits of microarrays as tools for studying neuropsychiatric disorders, Drugs Today (Barc) 40 (2004), 147-156.
30. E. Gr̈unblatt, S. Hoyer and P. Riederer, Gene expression profile in streptozotocin rat model for sporadic Alzheimer's disease, J Neural Transm 111 (2004), 367-386.
31. E. Gr̈unblatt, E. Koutsilieri, S. Hoyer and P. Riederer, Gene expression alterations in brain areas of intracerebroventricular streptozotocin treated rat, J Alzheimers Dis 9 (2006), 261-271.
32. E. Gr̈unblatt, S. Mandel, J. Jacob-Hirsch, S. Zeligson, N. Amariglo, G. Rechavi, J. Li, R. Ravid, W. Roggendorf, P. Riederer and M.B. Youdim, Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes, J Neural Transm 111 (2004), 1543-1573.
33. E. Gr̈unblatt, S. Mandel, G. Maor and M.B. Youdim, Gene expression analysis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R-apomorphine, J Neurochem 78 (2001), 1-12.
34. R. Hata, M. Masumura, H. Akatsu, F. Li, H. Fujita, Y. Nagai, T. Yamamoto, H. Okada, K. Kosaka, M. Sakanaka and T. Sawada, Up-regulation of calcineurin Abeta mRNA in the Alzheimer's disease brain: assessment by cDNA microarray, Biochem Biophys Res Commun 284 (2001), 310-316.
35. M.A. Hauser, Y.J. Li, H. Xu, M.A. Noureddine, Y.S. Shao, S.R. Gullans, C.R. Scherzer, R.V. Jensen, A.C. McLaurin, J.R. Gibson, B.L. Scott, R.M. Jewett, J.E. Stenger, D.E. Schmechel, C.M. Hulette and J.M. Vance, Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism, Arch Neurol 62 (2005), 917-921.
36. R.A. Heller, M. Schena, A. Chai, D. Shalon, T. Bedilion, J. Gilmore, D.E. Woolley and R.W. Davis, Discovery and analysis of inflammatory disease-related genes using cDNA microarrays, Proc Natl Acad Sci USA 94 (1997), 2150-2155.
37. L. Ho, Y. Guo, L. Spielman, O. Petrescu, V. Haroutunian, D. Purohit, A. Czernik, S. Yemul, P.S. Aisen, R. Mohs and G.M. Pasinetti, Altered expression of a-type but not b-type synapsin isoform in the brain of patients at high risk for Alzheimer's disease assessed by DNA microarray technique, Neurosci Lett 298 (2001), 191-194.
38. M.M. Hoehn and M.D. Yahr, Parkinsonism: onset, progression and mortality, Neurology 17 (1967), 427-442.
39. E.M. Hol, F.W. van Leeuwen and D.F. Fischer, The proteasome in Alzheimer's disease and Parkinson's disease: lessons from ubiquitin B + 1, Trends Mol Med 11 (2005), 488-495
40. C. Holmes, Genotype and phenotype in Alzheimer's disease, Br J Psychiatry 180 (2002), 131-134.
41. S. Hoyer and L. Fr̈olich, Brain function and insulin signal transduction in sporadic Alzheimer's disease, in: Research Progress in Alzheimer's Disease and Dementia, M.K. Sun, ed., Vol. In Press, 2006, Nova Science, New York.
42. C.P. Jacob, E.Koutsilieri, J. Bartl, E. Neuen-Jacob, T. Arzberger, N. Zander, R. Ravid, W. Roggendorf, P. Riederer and E. Gr̈unblatt, Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer's disease, J Alzheimers Dis 11 (2007), 97-116.
43. P.L. Katsel, K.L. Davis and V. Haroutunian, Large-scale microarray studies of gene expression in multiple regions of the brain in schizophrenia and Alzheimer's disease, Int Rev Neurobiol 63 (2005), 41-82.
44. I. Lastres-Becker and J. Fernandez-Ruiz, An overview of Parkinson's disease and the cannabinoid system and possible benefits of cannabinoid-based treatments, Curr Med Chem 13 (2006), 3705-3718.
45. J.M. Lewohl, L. Wang, M.F. Miles, L. Zhang, P.R. Dodd and R.A. Harris, Gene expression in human alcoholism: microarray analysis of frontal cortex, Alcohol Clin Exp Res 24 (2000), 1873-1882.
46. T. Li, T.H. Vu, G.A. Ulaner, E. Littman, J.Q. Ling, H.L. Chen, J.F. Hu, B. Behr, L. Giudice and A.R. Hoffman, IVF results in de novo DNA methylation and histone methylation at an Igf2-H19 imprinting epigenetic switch, Mol Hum Reprod 11 (2005), 631-640.
47. M.A. Pericak-Vance, C. Hulette and K.A. Welsh-Bohmer, Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease, Hum Mol Genet 12 (2003), 3259-3267.
48. Y.J. Li, W.K. Scott, L. Zhang, P.I. Lin, S.A. Oliveira, T. Skelly, M.P. Doraiswamy, K.A. Welsh-Bohmer, E.R. Martin, J.L. Haines, M.A. Pericak-Vance and J.M. Vance, Revealing the role of glutathione S-transferase omega in age-at-onset of Alzheimer and Parkinson diseases, Neurobiol Aging 27 (2006), 1087-1093.
49. D.A. Loeffler, J.R. Connor, P.L. Juneau, B.S. Snyder, L. Kanaley, A.J. DeMaggio, H. Nguyen, C.M. Brickman and P.A. LeWitt, Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions, J Neurochem 65 (1995), 710-724.
50. J.F. Loring, X. Wen, J.M. Lee, J. Seilhamer and R. Somogyi, A gene expression profile of Alzheimer's disease, DNA Cell Biol 20 (2001), 683-695.
51. L. Lu, F. Neff, D. Alvarez-Fischer, C. Henze, Y. Xie, W.H. Oertel, J. Schlegel and A. Hartmann, Gene expression profiling of Lewy body-bearing neurons in Parkinson's disease, Exp Neurol 195 (2005), 27-39.
52. G. Marsicano, B. Moosmann, H. Hermann, B. Lutz and C. Behl, Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1, J Neurochem 80 (2002), 448-456.
53. M.J. Marton, J.L. DeRisi, H.A. Bennett, V.R. Iyer, M.R. Meyer, C.J. Roberts, R. Stoughton, J. Burchard, D. Slade, H. Dai, D.E. Bassett, Jr., L.H. Hartwell, P.O. Brown and S.H. Friend, Drug target validation and identification of secondary drug target effects using DNA microarrays, Nat Med 4 (1998), 1293-1301.
54. P. Mecocci, R. Ekman, L. Parnetti and U. Senin, Antihistone and anti-dsDNA autoantibodies in Alzheimer's disease and vascular dementia, Biol Psychiatry 34 (1993), 380-385.
55. S. Mihailescu and R. Drucker-Colin, Nicotine, brain nicotinic receptors, and neuropsychiatric disorders, Arch Med Res 31 (2000), 131-144.
56. R.M. Miller, G.L. Kiser, T.M. Kaysser-Kranich, R.J. Lockner, C. Palaniappan and H.J. Federoff, Robust dysregulation of gene expression in substantia nigra and striatum in Parkinson's disease, Neurobiol Dis 21 (2006), 305-313.
57. J.C. Mills, K.A. Roth, R.L. Cagan and J.I. Gordon, DNA microarrays and beyond: completing the journey from tissue to cell, Nat Cell Biol 3 (2001), E175-E178.
58. R.L. Nussbaum and C.E. Ellis, Alzheimer's disease and Parkinson's disease, N Engl J Med 348 (2003), 1356-1364.
59. E.S. Onaivi, H. Ishiguro, J.P. Gong, S. Patel, A. Perchuk, P.A. Meozzi, L. Myers, Z. Mora, P. Tagliaferro, E. Gardner, A. Brusco, B.E. Akinshola, Q.R. Liu, B. Hope, S. Iwasaki, T. Arinami, L. Teasenfitz and G.R. Uhl, Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain, Ann N Y Acad Sci 1074 (2006), 514-536.
60. M.J. O'Neill, T.K. Murray, V. Lakics, N.P. Visanji and S. Duty, The role of neuronal nicotinic acetylcholine receptors in acute and chronic neurodegeneration, Curr Drug Targets CNS Neurol Disord 1 (2002), 399-411.
61. S. Papapetropoulos, J. Ffrench-Mullen, D. McCorquodale, Y. Qin, J. Pablo and D.C. Mash, Multiregional gene expression profiling identifies MRPS6 as a possible candidate gene for Parkinson's disease, Gene Expr 13 (2006), 205-215.
62. G.M. Pasinetti, Use of cDNA microarray in the search for molecular markers involved in the onset of Alzheimer's disease dementia, J Neurosci Res 65 (2001), 471-476.
63. M.R. Pazos, E. Nunez, C. Benito, R.M. Tolon and J. Romero, Role of the endocannabinoid system in Alzheimer's disease: new perspectives, Life Sci 75 (2004), 1907-1915.
64. C. Perez-Pastene, R. Graumann, F. Diaz-Grez, M. Miranda, P. Venegas, O.T. Godoy, L. Layson, R. Villagra, J.M. Matamala, L. Herrera and J. Segura-Aguilar, Association of GST M1 null polymorphism with Parkinson's disease in a Chilean population with a strong Amerindian genetic component. Neurosci Lett 418 (2007), 181-185.
65. M.S. Pollanen, D.W. Dickson and C. Bergeron, Pathology and biology of the Lewy body, J Neuropathol Exp Neurol 52 (1993), 183-191.
66. M.H. Polymeropoulos, Genetics of Parkinson's disease, Ann N Y Acad Sci 920 (2000), 28-32.
67. W.Q. Qiu and M.F. Folstein, Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis, Neurobiol Aging 27 (2006), 190-198.
68. D. Rajagopalan, A comparison of statistical methods for analysis of high density oligonucleotide array data, Bioinformatics 19 (2003), 1469-1476.
69. B.G. Ramirez, C. Blazquez, T. Gomez del Pulgar, M. Guzman and M.L. de Ceballos, Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation, J Neurosci 25 (2005), 1904-1913.
70. M. Schena, R.A. Heller, T.P. Theriault, K. Konrad, E. Lachenmeier and R.W. Davis, Microarrays: biotechnology's discovery platform for functional genomics, Trends Biotechnol 16 (1998), 301-306.
71. R.P. Sharma, D.R. Grayson, A. Guidotti and E. Costa, Chromatin, DNAmethylation and neuron gene regulation - the purpose of the package, J Psychiatry Neurosci 30 (2005), 257-263.
72. Q. Shi and E. Tao, An Ile93Met substitution in the UCH-L1 gene is not a disease-causing mutation for idiopathic Parkinson's disease, Chin Med J (Engl) 116 (2003), 312-313.
73. K.A. Sieradzan, S.H. Fox, M. Hill, J.P. Dick, A.R. Crossman and J.M. Brotchie, Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study, Neurology 57 (2001), 2108-2111.
74. N. Solowij and P.T. Michie, Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia? J Psychiatry Neurosci 32 (2007), 30-52.
75. E. Steen, B.M. Terry, E.J. Rivera, J.L. Cannon, T.R. Neely, R. Tavares, X.J. Xu, J.R.Wands and S.M. de la Monte, Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes? J Alzheimers Dis 7 (2005), 63-80.
76. J.H. Stockley and C. O'Neill, The proteins BACE1 and BACE2 and beta-secretase activity in normal and Alzheimer's disease brain, Biochem Soc Trans 35 (2007), 574-576.
77. J. Takahashi-Fujigasaki and H. Fujigasaki, Histone deacetylase (HDAC) 4 involvement in both Lewy and Marinesco bodies, Neuropathol Appl Neurobiol 32 (2006), 562-566.
78. D.R. Thal and H. Braak, [Post-mortem diagnosis of Alzheimer's disease], Pathologe 26 (2005), 201-213.
79. R. Vilar, H. Coelho, E. Rodrigues, M.J. Gama, I. Rivera, E. Taioli and M.C. Lechner, Association of A313 G polymorphism (GSTP1*B) in the glutathione-S-transferase P1 gene with sporadic Parkinson's disease, Eur J Neurol 14 (2007), 156-161.
80. I.R. Vogt, A.J. Lees, B.O. Evert, T. Klockgether, M. Bonin and U. Wullner, Transcriptional changes in multiple system atrophy and Parkinson's disease putamen, Exp Neurol 199 (2006), 465-478.
81. T.H. Vu, T. Li and A.R. Hoffman, Promoter-restricted histone code, not the differentially methylated DNA regions or antisense transcripts, marks the imprinting status of IGF2R in human and mouse, Hum Mol Genet 13 (2004), 2233-2245.
82. R.Weindruch, T. Kayo, C.K. Lee and T.A. Prolla, Microarray profiling of gene expression in aging and its alteration by caloric restriction in mice, J Nutr 131 (2001), 918S-923S.
83. R. Weindruch, T. Kayo, C.K. Lee and T.A. Prolla, Gene expression profiling of aging using DNA microarrays, Mech Ageing Dev 123 (2002), 177-193.
84. D. Weisman and I. McKeith, Dementia with Lewy bodies, Semin Neurol 27 (2007), 42-47.
85. P.J. Yao, M. Zhu, E.I. Pyun, A.I. Brooks, S. Therianos, V.E. Meyers and P.D. Coleman, Defects in expression of genes related to synaptic vesicle trafficking in frontal cortex of Alzheimer's disease, Neurobiol Dis 12 (2003), 97-109.
86. T. Yoshihara, S. Ishigaki, M. Yamamoto, Y. Liang, J. Niwa, H. Takeuchi, M. Doyu and G. Sobue, Differential expression of inflammation- and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis, J Neurochem 80 (2002), 158-167.
87. Y. Zhang, M. James, F.A. Middleton and R.L. Davis, Transcriptional analysis of multiple brain regions in Parkinson's disease supports the involvement of specific protein processing, energy metabolism, and signaling pathways, and suggests novel disease mechanisms, Am J Med Genet B Neuropsychiatr Genet 137 (2005), 5-16.